1. Biosenz B.V. – A Lavoisier Company - Zernikepark 16 9747AN Groningen – 050 8508960- info@biosenz.nl - www.biosenz.nl
ViriChip™ System:
A platform technology for virus
detection and identification
Johan Oosterheert, Managing director
September 24, 2015

2. 9/28/2015 Strictly confidential
New 'Sars-like' coronavirus identified by UK officials
By Michelle Roberts Health editor, BBC News online, September 2012
A new respiratory illness similar to the Sars virus that spread globally in 2003 and killed hundreds
of people has been identified in a man who is being treated in Britain. The 49-year-old man, who
was transferred to a London hospital by air ambulance from Qatar, is the second person confirmed
with the corona virus. The first case was a patient in Saudi Arabia who has since died. Officials are
still determining what threat the new virus may pose.
Infectious viruses pose a serious threat
to public health
• Current diagnostic systems for
viruses use central labs
• Identification may take several days

3. ViriChip™ shortens response time
dramatically
9/28/2015 Strictly confidential
The ViriChip™ System brings the Lab to the field!
The ViriChip™ System:
• Size of a shoe box
• On-the-spot detection
and identification
• 30 minutes response time

4. ViriChip™ is a unique, patented
lab-on-a chip technology
9/28/2015 Strictly confidential
Nano - and Biotechnology Atomic Force Microscopy
Ligand capture
Biosenz holds exclusive world-wide license on several patents

5. Biosenz has validated the technology
9/28/2015 Strictly confidential
Silicon chip including antibodies with Coxsackie B3 virus attached
Biosenz has validated 15 different viruses

6. ViriChip offers sensitivity, specificity,
ease of use and speed
9/28/2015 Strictly confidential
ViriChip PCR Immuno
assays
Immuno
electron
Microscopy
Cell culture RAMP
Response
time
Integral
cost/test
Sensitivity
Specificity
Portability
Ease of use
Bulk
processing

7. Biosenz intends to sell Virichip in
multiple markets
9/28/2015 Strictly confidential
1 2 3 4 5 6 7 8
Veterinary
Food
Clinical Markets
CDC, Homeland Security,
Defense
Research Institutes
US Bio-defense
busget $ 6.4 Bln. In
2012
World In-vitro
diagnostic market
$ 40 Bln. (2010)
POCT for infectious
diseases $ 843 M
(2011); 14% CAGR

8. Biosenz operates as a network organization
9/28/2015 Strictly confidential

9. ViriChip presents a unique opportunity
• Current diagnostic methods used to identify viruses
use central labs and take days
• ViriChip technology brings the lab to the field,
reducing response time to ~30 minutes
• Significant market potential
• Limited risk through business model and team
9/28/2015 Strictly confidential

10. Thank you for your attention.
9/28/2015 Strictly confidential